Company Overview - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases [3] - The company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, aimed at inhibiting the activity of B cells involved in autoimmune diseases without depleting them [3] - Zenas aims to leverage its experienced leadership and disciplined product acquisition strategy to identify and develop candidates that provide superior clinical benefits for patients with autoimmune diseases [3] Stock Option Grant - On June 16, 2025, Zenas granted a non-qualified stock option to purchase 112,000 shares of common stock to a newly hired employee as an inducement for employment [1] - The stock option has a ten-year term with an exercise price of $9.97, equal to the closing price on the grant date [2] - The option will vest over four years, with 25% vesting on the one-year anniversary of employment and the remainder vesting in 36 equal monthly installments, contingent on the employee's continued service [2]

Core Viewpoint - A class action lawsuit has been filed against Zenas BioPharma, Inc. for violations of federal securities laws related to misleading statements made during its IPO [1][4]. Group 1: Lawsuit Details - The lawsuit is initiated by the Schall Law Firm, which specializes in shareholder rights litigation [1][5]. - Investors who purchased Zenas securities during its IPO on September 13, 2024, are encouraged to contact the firm for participation in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Zenas BioPharma - The complaint alleges that Zenas made false and misleading statements regarding its financial status, specifically overstating the runway of funded operations based on existing cash and expected IPO proceeds [4]. - The misleading public statements were made throughout the IPO period, leading to investor damages once the truth was revealed [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Zenas BioPharma, Inc. regarding a class action lawsuit related to misleading statements made during the company's initial public offering in September 2024 [1][2]. Allegations - The complaint alleges that Zenas BioPharma materially overstated its ability to fund operations with existing cash and expected net proceeds from the IPO, leading to false and misleading public statements [2]. Class Action Details - The class period for the lawsuit includes shareholders who purchased ZBIO securities during the time of the IPO registration statement and related prospectus [1]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is June 16, 2025 [3]. Next Steps for Shareholders - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates on the case's status [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements [4].

Core Viewpoint - A class action lawsuit has been filed against Zenas Biopharma, Inc. for alleged violations of federal securities laws related to misleading statements made during its IPO [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Zenas Biopharma overstated the sustainability of its operations based on existing cash and expected IPO proceeds, leading to false and misleading public statements during the IPO period [2]. - Investors who purchased securities linked to the IPO on September 13, 2024, are encouraged to contact the law firm before June 16, 2025, to participate in the lawsuit [1][2]. Group 2: Law Firm Background - DJS Law Group specializes in securities class actions, corporate governance litigation, and M&A appraisals, focusing on enhancing investor returns through advocacy [3]. - The firm represents large hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [3].

Core Viewpoint - Rosen Law Firm is reminding investors of Zenas BioPharma, Inc. about the upcoming lead plaintiff deadline in a securities class action related to the company's IPO in September 2024 [1]. Group 1: Class Action Details - Investors who purchased Zenas BioPharma securities may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by June 16, 2025, to serve as lead plaintiff [3]. - The lawsuit alleges that the Registration Statement contained false or misleading statements regarding the company's financial situation and operational funding [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of materially false and misleading statements regarding its financial status and operational funding capabilities during its initial public offering in September 2024 [2]. Group 1: Allegations - The complaint claims that Zenas BioPharma overstated the duration it could fund its operations with existing cash and expected net proceeds from the IPO [2]. - As a result of these misstatements, the public statements made by the defendants were deemed materially false and misleading throughout the relevant period [2]. Group 2: Class Action Details - The class period for the lawsuit includes shareholders who purchased ZBIO securities during the time of the IPO registration statement and related prospectus [1]. - Shareholders are encouraged to register for the class action by June 16, 2025, to potentially be appointed as lead plaintiffs [3]. - There is no cost or obligation for shareholders to participate in the case, and they will receive updates through a portfolio monitoring software [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [4].

SAN DIEGO, June 11, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma’s registration statement issued in connection with Zenas BioPharma’s initial public offering (the “IPO”) held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Captioned Buathongsri ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's financial status and IPO funding [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Zenas to contact them directly to discuss their legal options [1]. - A federal securities class action has been filed against Zenas, with a deadline of June 16, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Zenas materially overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to misleading public statements [4]. Group 2: Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who directs the litigation on behalf of the class [5]. - Any member of the class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5]. Group 3: Additional Information - Faruqi & Faruqi encourages anyone with information regarding Zenas' conduct, including whistleblowers and former employees, to contact the firm [6].

Core Viewpoint - A class action securities lawsuit has been filed against Zenas BioPharma, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's September 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to Zenas BioPharma's IPO [2]. - The complaint alleges that Zenas BioPharma materially overstated its ability to fund operations using existing cash and expected net proceeds from the IPO, leading to false and misleading public statements [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Zenas BioPharma during the relevant time frame have until June 16, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securing compensation for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of materially false and misleading statements regarding its financial status and operational funding during its initial public offering in September 2024 [2]. Group 1: Allegations - The complaint claims that Zenas BioPharma overstated its ability to fund operations with existing cash and expected net proceeds from the IPO [2]. - It is alleged that the public statements made by the defendants were materially false and misleading throughout the relevant period [2]. Group 2: Class Action Details - The class period for the lawsuit includes shareholders who purchased ZBIO securities during the time of the IPO registration statement [1]. - Shareholders are encouraged to register for the class action by June 16, 2025, to potentially become lead plaintiffs [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].